Ocular Therapeutix (OCUL) Non Operating Income (2013 - 2026)
Ocular Therapeutix's quarterly Non Operating Income came in at $4.7 million in Q1 2026, up 3576.47% year-on-year from $128601.6 in Q1 2025, and down 7.4% quarter-over-quarter from $5.1 million in Q4 2025.
Ocular Therapeutix has reported Non Operating Income for 14 years, with the latest figure at $4.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 3576.47% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (down 21.36% YoY), and the FY2025 full-year result was $4.1 million, up 118.77% from the prior year.
- Non Operating Income for Q1 2026 stood at $4.7 million, down from $5.1 million in the prior quarter.
- The five-year high for Non Operating Income was $18.7 million in Q3 2023, with the low at -$33.2 million in Q1 2024.
- Average Non Operating Income over 5 years is $241823.5, with a median of -$1000.0 recorded in 2023.
- Year-over-year, Non Operating Income surged 114900.0% in 2022 and plunged 3323000.0% in 2024.
- Tracing OCUL's Non Operating Income over 5 years: stood at $3.8 million in 2022, then tumbled by 340.12% to -$9.2 million in 2023, then jumped by 123.86% to $2.2 million in 2024, then surged by 133.36% to $5.1 million in 2025, then dropped by 7.4% to $4.7 million in 2026.
- The last three Non Operating Income figures came in at $4.7 million (Q1 2026), $5.1 million (Q4 2025), and -$720000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 4.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.73 Mn |
| Dec 31, 2025 | 5.11 Mn |
| Sep 30, 2025 | -720,000.00 |
| Jun 30, 2025 | -173,000.00 |
| Mar 31, 2025 | -136,000.00 |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 9.51 Mn |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | -33.23 Mn |
| Dec 31, 2023 | -9.17 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | -112,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | 3.82 Mn |
| Sep 30, 2022 | -2.64 Mn |
| Jun 30, 2022 | 1.15 Mn |
| Mar 31, 2022 | 5.29 Mn |
| Dec 31, 2021 | 14.20 Mn |
| Sep 30, 2021 | 22.19 Mn |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 23.35 Mn |
| Dec 31, 2020 | -71.27 Mn |
| Sep 30, 2020 | 2.06 Mn |
| Jun 30, 2020 | -18.68 Mn |
| Mar 31, 2020 | -4.90 Mn |
| Sep 30, 2019 | -8,000.00 |
| Jun 30, 2019 | -2.85 Mn |
| Mar 31, 2019 | 2.53 Mn |
| Dec 31, 2018 | -116,000.00 |
| Sep 30, 2018 | -194,000.00 |
| Jun 30, 2018 | -240,000.00 |
| Mar 31, 2018 | -310,000.00 |
| Dec 31, 2017 | -386,000.00 |
| Sep 30, 2017 | -371,000.00 |
| Jun 30, 2017 | -355,000.00 |
| Mar 31, 2017 | -351,000.00 |
| Sep 30, 2016 | -1,000.00 |
| Jun 30, 2016 | -338,000.00 |
| Mar 31, 2016 | -331,000.00 |
| Dec 31, 2015 | 1.20 Mn |
| Sep 30, 2015 | 3,000.00 |
| Jun 30, 2015 | 3,000.00 |
| Mar 31, 2015 | -465,000.00 |
| Dec 31, 2014 | -1.11 Mn |
| Sep 30, 2014 | -111,000.00 |
| Jun 30, 2014 | -446,000.00 |
| Mar 31, 2014 | -183,000.00 |
| Dec 31, 2013 | 342,000.00 |
| Sep 30, 2013 | 4,000.00 |
| Jun 30, 2013 | 3,000.00 |